Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds

ACS Chemical Biology

Volumn 4, Issue 11, 2009, Pages 939-947

  Emert Sedlak, Lori ^a   Kodama, Toshiaki ^a   Lerner, Edwina C ^a   Dai, Weixiang ^b   Foster, Caleb ^a   Day, Billy W ^a,b   Lazo, John S ^a   Smithgall, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIPHENYLFUROPYRIMIDINE; HEMATOPOIETIC CELL KINASE; NEF PROTEIN; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TARGET VARIABLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HIGH-THROUGHPUT SCREENING ASSAYS; HIV-1; HUMANS; MOLECULAR STRUCTURE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-HCK; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73449135109     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb900195c     Document Type: Article

References (37)

1. Fackler, O. T., and Baur, A. S. (2002) Live and let die: Nef functions beyond HIV replication, Immunity 16, 493-497.
2. Joseph, A. M., Kumar, M., and Mitra, D. (2005) Nef: "necessary and enforcing factor" in HIV infection, Curr. HIV Res. 3, 87-94.
3. Kestler, H., Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991) Importance of the nef gene for maintenance of high viral loads and for development of AIDS, Cell 65, 651-662.
4. Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C., Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J., Sullivan, J. S., Cunningham, A., Dwyer, D., Dowton, D., and Mills, J. (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients, Science 270, 988-991.
5. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L., and Desrosiers, R. C. (1995) Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection, N. Engl. J. Med. 332, 228-232.
6. Mariani, R., Kirchhoff, F., Greenough, T. C., Sullivan, J. L., Desrosiers, R. C., and Skowronski, J. (1996) High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection, J. Virol. 70, 7752-7764.
7. Herna, R. G., and Saksela, K. (2000) Interactions of HIV-1 NEF with cellular signal transducing proteins, Front Biosci. 5, D268-D283.
8. Arold, S. T., and Baur, A. S. (2001) Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein, Trends Biochem. Sci. 26, 356-363.
9. Geyer, M., Fackler, O. T., and Peterlin, B. M. (2001) Structure-function relationships in HIV-1 Nef, EMBO Rep. 2, 580-585.
10. Briggs, S. D., Scholtz, B., Jacque, J. M., Swingler, S., Stevenson, M., and Smithgall, T. E. (2001) HIV-1 Nef promotes survival of myeloid cells by a Stat3-dependent pathway, J. Biol. Chem. 276, 25605-25611.
11. Choi, H.-J., and Smithgall, T. E. (2004) HIV-1 Nef promotes survival of TF-1 macrophages by inducing Bcl-XL expression in an Erk-dependent manner, J. Biol. Chem. 279, 51668-51696.
12. Geleziunas, R., Xu, W., Takeda, K., Ichijo, H., and Greene, W. C. (2001) HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell, Nature 410, 834-838.
13. + viruses but not for down-regulation of CD4, EMBO J. 14, 484-491.
14. Arold, S., Franken, P., Strub, M. P., Hoh, F., Benichou, S., Benarous, R., and Dumas, C. (1997) The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling, Structure 5, 1361-1372.
15. Choi, H. J., and Smithgall, T. E. (2004) Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase, J. Mol. Biol. 343, 1255-1268.
16. Arold, S., O'Brien, R., Franken, P., Strub, M. P., Hoh, F., Dumas, C., and Ladbury, J. E. (1998) RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef, Biochemistry 37, 14683-14691.
17. Moarefi, I., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C.-H., Kuriyan, J., and Miller, W. T. (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement, Nature 385, 650-653.
18. Briggs, S. D., Sharkey, M., Stevenson, M., and Smithgall, T. E. (1997) SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1, J. Biol. Chem. 272, 17899-17902.
19. Trible, R. P., Emert-Sedlak, L., and Smithgall, T. E. (2006) HIV-1 Nef selectively activates SRC family kinases HCK, LYN, and c-SRC through direct SH3 domain interaction, J. Biol. Chem. 281, 27029-27038.
20. Komuro, I., Yokota, Y., Yasuda, S., Iwamoto, A., and Kagawa, K. S. (2003) CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection, J. Exp. Med. 198, 443-453.
21. Hanna, Z., Kay, D. G., Rebai, N., Guimond, A., Jothy, S., and Jolicoeur, P. (1998) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice, Cell 95, 163-175.
22. Hanna, Z., Weng, X., Kay, D. G., Poudrier, J., Lowell, C., and Jolicoeur, P. (2001) The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck, J. Virol. 75, 9378-9392.
23. Lerner, E. C., and Smithgall, T. E. (2002) SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo, Nat. Struct. Biol. 9, 365-369.
24. Boggon, T. J., and Eck, M. J. (2004) Structure and regulation of Src family kinases, Oncogene 23, 7918-7927.
25. Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., and Kuriyan, J. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor, Mol. Cell 3, 639-648.
26. Zhang, J. H., Chung, T. D. Y., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays, J. Biomol. Screen. 4, 67-73.
27. Ruegg, U. T., and Burgess, G. M. (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases, Trends Pharmacol. Sci. 10, 218-220.
28. Trkola, A., Ketas, T., Kewalramani, V. N., Endorf, F., Binley, J. M., Katinger, H., Robinson, J., Littman, D. R., and Moore, J. P. (1998) Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage, J. Virol. 72, 1876-1885.
29. Salvatori, F., and Scarlatti, G. (2001) HIV type 1 chemokine receptor usage in mother-to-child transmission, AIDS Res. Hum. Retroviruses 17, 925-935.
30. Dimauro, E. F., Newcomb, J., Nunes, J. J., Bemis, J. E., Boucher, C., Buchanan, J. L., Buckner, W. H., Cheng, A., Faust, T., Hsieh, F., Huang, X., Lee, J. H., Marshall, T. L., Martin, M. W., McGowan, D. C., Schneider, S., Turci, S. M., White, R. D., and Zhu, X. (2007) Discovery of 4-amino-5,6-biaryl- furo[2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR, Bioorg. Med. Chem. Lett. 17, 2305-2309.
31. Pene-Dumitrescu, T., Peterson, L. F., Donato, N. J., and Smithgall, T. E. (2008) An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broadspectrum Src family kinase inhibitor A-419259, Oncogene 27, 7055-7069.
32. Temesgen, Z., Warnke, D., and Kasten, M. J. (2006) Current status of antiretroviral therapy, Expert. Opin. Pharmacother. 7, 1541-1554.
33. Greene, W. C. (2004) The brightening future of HIV therapeutics, Nat. Immunol. 5, 867-871.
34. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T., and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets, Blood 110, 4055-4063.
35. Trible, R. P., Emert-Sedlak, L., Wales, T. E., Ayyavoo, V., Engen, J. R., and Smithgall, T. E. (2007) Allosteric loss-of-function mutations in HIV-1 Nef from a long-term non-progressor, J. Mol. Biol. 374, 121-129.
36. Gewald, K. (1966) Heterocycles from CH-acidic nitriles. IX. Reaction of a-hydroxy ketones with malononitrile, Chem. Ber. 99, 1002-1007.
37. Smith, S. D., Shatsky, M., Cohen, P. S., Warnke, R., Link, M. P., and Glader, B. E. (1984) Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines, Cancer Res. 44, 5657-5660.